DAB2IP is inactivated in cancers through promoter methylation involving the EZH2-PRC2 complex, phosphorylation by AKT1, posttranscriptional silencing by microRNAs, and degradation by E3-ubiquitin ligases (24). Here, EZH2 is linked to cancer.